<DOC>
	<DOCNO>NCT01752153</DOCNO>
	<brief_summary>A wide spectrum immune abnormality describe numerous study involve β-thalassemic patient multiple transfusion . The abnormality observe quantitative functional , concern several component immune response . Flavonoids phenolic compound widely distribute plant , report exert multiple biological effect , include antioxidant free radical scavenging ability . Silymarin , flavonolignan complex isolate milk thistle ( Silybum marianum L. Gaertn ) , classify cytoprotective , antioxidant , anti-inflammatory , especially hepatoprotective agent . Silymarin already use clinically treatment liver diseases.It consider safe well-tolerated , report adverse event similar placebo . Several study also report immunomodulatory action silymarin . It increase lymphocyte proliferation , interferon gamma , interleukin ( IL ) -4 IL-10 secretion stimulate lymphocytes dose-dependent manner . It show vitro treatment peripheral blood mononuclear cell silymarin cause restoration thiol status increase T cell proliferation activation . Because reactive oxygen specie iron overload play important role pathophysiology thalassemia , silymarin may effective therapy due antioxidant , immunomodulatory , cytoprotective iron chelating activity . The present study design investigate therapeutic activity orally administer silymarin treatment β-thalassemia major , well-known prevalent disease Iran , associate oxidative stress , iron overload immune abnormality .</brief_summary>
	<brief_title>Immunomodulatory Effects Silymarin Patients With Beta-Thalassemia Major</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Homozygous betathalassemia major Regularly blood transfusion Iron chelation therapy subcutaneous desferrioxamine ( DFO ) 40.0 mg/Kg/day 57 days/week Chronic hepatitis B infection Active hepatitis C infection A history positive HIV test Chronic renal heart failure Iron chelation therapy deferiprone Pregnancy Gastrointestinal condition prevent absorption oral medication noncompliance prescribe therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Focus</keyword>
	<keyword>immunomodulatory effect</keyword>
	<keyword>silymarin</keyword>
	<keyword>cell mediate immunity</keyword>
	<keyword>Beta-Thalassemia</keyword>
	<keyword>major patient .</keyword>
</DOC>